Q2 STOCKS TO BUY

Analyst Update: Regeneron Pharma, Kite Pharma, E2open

Analysts adjusted their ratings on Regeneron Pharmaceuticals Inc (REGN), Kite Pharma Inc (KITE), and E2open Inc (EOPN)

Jan 9, 2015 at 2:46 PM
facebook X logo linkedin


Analysts are weighing in today on biopharmaceutical companies Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Kite Pharma Inc (NASDAQ:KITE), as well as cloud concern E2open Inc (NASDAQ:EOPN). Here's a quick look at today's brokerage notes on REGN, KITE, and EOPN.

  • This morning, REGN and Sanofi SA (ADR) (NYSE:SNY) announced that their cholesterol drug, alirocumab, met its primary efficacy endpoints in two trials. Shortly after this news was released, Goldman Sachs bumped REGN's price target to $486 from $480 --never before seen territory -- and the security has benefited by adding 3% to trade at $415.55. Ten out of 17 covering analysts already rate the shares a "buy" or better, but the seven others maintain "hold" recommendations, and the consensus 12-month price target of $423.29 stands just 1.5% above current trading levels, meaning upgrades and/or additional price-target hikes could be coming. Regeneron Pharmaceuticals Inc may also benefit from a short-squeeze situation, should its rally continue, as over 6% of its float is sold short -- a figure that represents exactly seven days' worth of pent-up buying power, at the security's average daily pace of trading.

  • KITE's hot streak is continuing today, after Mizuho initiated coverage on the equity with a "buy" rating, pushing it over 11% higher to $78.98 -- after earlier topping out at an all-time high of $80.14. Since going public in late June, Kite Pharma Inc has more than tripled in value, and is now trading north of its consensus 12-month price target of $79.40. While good news for shareholders, this marks another bad day for the KITE shorts who have piled on recently..

  • EOPN flopped to an all-time low of $5.21 today after its worse-than-expected fourth-quarter earnings and revenue prompted negative analyst attention. Specifically, Canaccord Genuity and Benchmark both downgraded the stock to "hold" from "buy," with the former slashing its price target to $7 from $13, and the latter cutting its target to $6. Also weighing on E2open Inc -¬ which was last seen 37.46% lower at $5.51 -- is a downgrade to "market perform" from "outperform" at William Blair. The security's year-over-year decline is now nearly 78%, which should please a large portion of traders, as roughly 14.5% of EOPN's float is sold short.
 
 

“Buy This Stock Now!” - Expert Who Called 11x On TSLA

He called a rare 11x on Tesla…

But now, thanks to Elon & Trump’s new alliance…

He says there’s a new opportunity that could be 1,000x BIGGER than Tesla – and it could completely revolutionize a $23 Trillion market.

It’s trading for less than $5 per share right now…

But it won’t be under the radar for long.

Discover The 1,000x Bigger Elon Opportunity Here

GRAND SLAM COUNTDOWN

 
 

Featured Articles from Trusted Partners:

👀Learn How Dividends Create Passive Income for Life
Receive $200 Off Motley Fool Epic. The Motley Fool Epic $299 discounted offer is based on $499/year list price. Introductory promotion for new members only. Take control of your money and your portfolio with Motley Fool Epic.

💵New Income System Could Pay You $4,243 Monthly
You could collect an average of $4,243 per month starting as early as next week with a new payout system for income investors. New registrations are being accepted for investors who want to be in a position to start with their first payout next week.

🚀Easy 92% Crypto Dividends (No Coins Required)
COIN stock doesn't pay a dividend... But there's actually a new way to collect a massive dividend that's indirectly based on the stock and offers a terrific monthly income (currently yielding nearly 92% on a forward basis).

🤝Free Advisor Match with Wiseradvisor.com
Don't leave your retirement to chance! Get matched with a trusted financial expert for FREE and make the most of your tax refund. Get started now.

⚠️Dennis Quaid's #1 Warning for Americans
Here's the thing: life doesn't come with guarantees. The economy shifts, markets stumble, and years of hard work could slip through your fingers like sand. But it doesn't have to be that way for you. So request a free copy of this Gold & Silver Guide that will arrive right to your doorstep when you act now.

 

 
 

Follow us on X, Follow us on Twitter